Temodar
Active substance: Temozolomide
Manufacturer: Schering-Plough
Extract from the prescribing information:
"Patients treated with TEMODAR Capsules may experience myelosuppression."
"Temozolomide was mutagenic in vitro in bacteria (Ames assay) and clastogenic in mammalian cells (human peripheral blood lymphocyte assays)."
The above has been extracted from the Temodar prescribing information on the Schering-Plough webpages.